|
注册号: Registration number: |
ChiCTR2500110447 |
|
最近更新日期: Date of Last Refreshed on: |
2025-10-14 10:32:14 |
|
注册时间: Date of Registration: |
2025-10-14 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于PDSA循环减少极/超早产儿BPD的持续质量改进(四川省多中心)项目 |
|
Public title: |
Continuous Quality Improvement Based on the PDSA Cycle to Reduce Bronchopulmonary Dysplasia (BPD) in Extremely/Very Preterm Infants |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于PDSA循环减少极/超早产儿BPD的持续质量改进(四川省多中心) |
|
Scientific title: |
Continuous Quality Improvement Based on the PDSA Cycle to Reduce Bronchopulmonary Dysplasia (BPD) in Extremely/Very Preterm Infants |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李巧 |
研究负责人: |
傅益永 |
|
Applicant: |
Qiao Li |
Study leader: |
Yiyong Fu |
|
申请注册联系人电话: Applicant telephone: |
+86 183 2343 1554 |
研究负责人电话:
Study leader's |
+86 158 2806 3621 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
18883913606@163.com |
研究负责人电子邮件: Study leader's E-mail: |
xiaofoo000@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
成都市妇女儿童中心医院 |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
|
|
申请注册联系人通讯地址: |
成都市青羊区日月大道1617号 |
研究负责人通讯地址: |
成都市青羊区日月大道1617号 |
|
Applicant address: |
No. 1617, Riyue Avenue, Qingyang District, Chengdu, Sichuan Province, China. |
Study leader's address: |
No. 1617, Riyue Avenue, Qingyang District, Chengdu, Sichuan Province, China. |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
成都市妇女儿童中心医院 |
||
|
Applicant's institution: |
Chengdu Women's and Children's Central Hospital |
||
|
研究负责人所在单位: |
成都市妇女儿童中心医院 |
||
|
Affiliation of the Leader: |
Chengdu Women's and Children's Central Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
科研伦审2025(74)-2号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
成都市妇女儿童中心医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Chengdu Women's and Children's Central Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-08-11 00:00:00 | ||
|
伦理委员会联系人: |
唐丽娟 |
||
|
Contact Name of the ethic committee: |
Lijuan Tang |
||
|
伦理委员会联系地址: |
成都市青羊区日月大道1617号 |
||
|
Contact Address of the ethic committee: |
No. 1617, Riyue Avenue, Qingyang District, Chengdu, Sichuan Province, China. |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 6186 6009 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
成都市妇女儿童中心医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Chengdu Women's and Children's Central Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
成都市青羊区日月大道1617号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 1617, Riyue Avenue, Qingyang District, Chengdu, Sichuan Province, China. |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
北京医卫健康公益基金会 |
||||||||||||||||||||||
|
Source(s) of funding: |
Beijing Health and Health Public Welfare Foundation |
||||||||||||||||||||||
|
研究疾病: |
支气管肺发育不良 |
||||||||||||||||||||||
|
Target disease: |
Bronchopulmonary dysplasia(BPD) |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
作为牵头单位联合四川省其他 14 家医疗机构开展极/超早产儿生后“黄金1小时 ”持续质量改进(quality improvement,QI)。在患儿生后 60min 内从以下七个方面进行管理措施的改进:1)产前咨询和团队组建;2)胎盘输血;3)体温管理;4)呼吸支持;5)脐血管理;6)循环管理;7)感染预防,具体管理措施 形成《早产儿管理手册》,由参与单位参照执行。收集改进前后患儿的临床资料并比较患儿结局,了解质量改进成效,及时修定临床措施,保障改进效果的实现。 |
||||||||||||||||||||||
|
Objectives of Study: |
As the leading institution, we collaborated with 14 other medical facilities in Sichuan Province to implement continuous quality improvement (QI) for the "Golden Hour" after birth in extremely/very preterm infants. Within 60 minutes after delivery, management measures were enhanced across the following seven aspects: 1) prenatal consultation and team formation; 2) placental blood transfusion; 3) temperature management; 4) respiratory support; 5) umbilical cord blood management; 6) circulation management; and 7) infection prevention. Specific management protocols were compiled into the "Preterm Infant Management Manual," which was adopted by all participating institutions for reference and implementation. Clinical data of infants before and after the improvement were collected and compared to assess patient outcomes, evaluate the effectiveness of the quality improvement initiatives, and facilitate timely revisions of clinical measures to ensure the achievement of improved outcomes. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
无排除标准 |
||||||||||||||||||||||
|
Exclusion criteria: |
no exclusion critieria |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-06-01 00:00:00至 To 2026-12-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-10-20 00:00:00 至 To 2026-12-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
拟2026.1.1提交数据至医院伦理会 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
we paln to submit the data to the hospital ethics committee on January 1, 2026. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
通过Resman采集和管理数据 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Collecting and managing data through Resman |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |